Therapeutic drug monitoring for mycophenolic acid is value for (Little) money

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 2, 2011, Pages 203-204

  Van Gelder, T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

CONCENTRATION RESPONSE; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MONEY; PRIORITY JOURNAL; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION;

EID: 79960568419     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.96     Document Type: Review

References (10)

1. Holt, D.W., Marsden, J.T., Johnston, A., Bewick, M. & Taube, D.H. Blood cyclosporin concentrations and renal allograft dysfunction. Br. Med. J. 293, 1057-1059 (1986). (Pubitemid 17201408)
2. van Gelder, T. et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68, 261-266 (1999). (Pubitemid 29360288)
3. Le Meur, Y. et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transplant. 7, 2496-2503 (2007). (Pubitemid 47566324)
4. van Gelder, T. et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86, 1043-1051 (2008).
5. van Gelder, T. et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 89, 595-599 (2010).
6. Gaston, R.S. et al. Fixed-or controlled-dose mycophenolate mofetil with standard-or reduceddose calcineurin inhibitors: the Opticept trial. Am. J. Transplant. 9, 1607-1619 (2009).
7. Hazzan, M. et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J. Am. Soc. Nephrol. 16, 2509-2516 (2005). (Pubitemid 41725071)
8. Gourishankar, S. et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin. J. Am. Soc. Nephrol. 5, 1282-1289 (2010).
9. Glander, P. et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin. J. Am. Soc. Nephrol. 5, 503-511 (2010).
10. Rousseau, A. et al. Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. Transplantation 89, 1255-1262 (2010).